XOMA Corp (XOMA):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】XOMA Corp (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10127)・商品コード:DATA904C10127
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:63
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358, X213 and X129. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 (formerly LFA 102) is an allosteric inhibitor of prolactin action; X129 is a potent fragment of a monoclonal antibody with negative allosteric modulation activity. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corp (XOMA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
XOMA Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XOMA Corp, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 12
XOMA to Acquire Assets from Enumeral Biomedical for USD1.6 Million 13
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 14
Private Equity 15
XOMA Sells Royalty Rights to HealthCare Royalty Partners 15
Partnerships 16
Domain Therapeutics Enters into Agreement with Xoma 16
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 17
Licensing Agreements 18
Rezolute Enters into Licensing Agreement with XOMA 18
Tizona Therapeutics Enters into Licensing Agreement with XOMA 19
LakePharma Enters into Licensing Agreement with XOMA 20
Torch Biosciences Enters into Licensing Agreement with XOMA 21
PRLA Pharma Enters into Licensing Agreement with XOMA 22
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 23
Novartis Enters into Licensing Agreement with XOMA 24
Xoma Plans To Enter Into Licensing Agreement For Perindopril 25
Xoma Enters into Licensing Agreement with Texas A&M University System 26
Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise 27
XOMA Enters into Licensing Agreement with Margaux Biologics for BPI 28
Equity Offering 29
XOMA Plans to Raise USD20 Million in Subscription Rights Offering 29
XOMA Files Registration Statement for Public Offering of Securities 30
Xoma Raises USD25 Million in Registered Direct Offering of Shares 31
Xoma Raises USD40 Million in Private Placement of Shares and Warrants 32
Xoma Completes Public Offering Of Shares For US$57.4 Million 34
Xoma Completes Public Offering Of Shares For US$31.6 Million 36
Xoma Completes Public Offering Of Shares For US$40 Million 37
XOMA Completes Public Offering Of Common Stock For US$39 Million 39
Asset Transactions 41
Agenus Acquires Antibody Manufacturing Facilities from XOMA 41
Nanotherapeutics Ammends agreement with XOMA 43
CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 44
XOMA Corp – Key Competitors 45
XOMA Corp – Key Employees 46
XOMA Corp – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Nov 07, 2018: XOMA reports third quarter 2018 financial results 48
Aug 07, 2018: XOMA reports second quarter 2018 financial results 49
May 09, 2018: XOMA Reports First Quarter 2018 Financial Results 50
Mar 07, 2018: XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 51
Nov 06, 2017: XOMA Reports Third Quarter 2017 Financial Results 53
Aug 08, 2017: XOMA Reports Second Quarter 2017 Financial Results 54
May 09, 2017: XOMA Reports First Quarter 2017 Financial Results 55
Mar 16, 2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results 56
Corporate Communications 58
Feb 16, 2017: XOMA Appoints Matthew Perry to its Board of Directors 58
Product News 59
03/23/2017: XOMA Provides Update On New Drug Candidate At The 2017 ENDO Meeting 59
Clinical Trials 60
Apr 18, 2017: XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program 60
Mar 28, 2017: XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting 61
Other Significant Developments 62
Jun 26, 2018: XOMA Added to the Russell 2000 and Russell 3000 Indexes 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
XOMA Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Deals By Therapy Area, 2012 to YTD 2018 9
XOMA Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 12
XOMA to Acquire Assets from Enumeral Biomedical for USD1.6 Million 13
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 14
XOMA Sells Royalty Rights to HealthCare Royalty Partners 15
Domain Therapeutics Enters into Agreement with Xoma 16
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 17
Rezolute Enters into Licensing Agreement with XOMA 18
Tizona Therapeutics Enters into Licensing Agreement with XOMA 19
LakePharma Enters into Licensing Agreement with XOMA 20
Torch Biosciences Enters into Licensing Agreement with XOMA 21
PRLA Pharma Enters into Licensing Agreement with XOMA 22
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 23
Novartis Enters into Licensing Agreement with XOMA 24
Xoma Plans To Enter Into Licensing Agreement For Perindopril 25
Xoma Enters into Licensing Agreement with Texas A&M University System 26
Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise 27
XOMA Enters into Licensing Agreement with Margaux Biologics for BPI 28
XOMA Plans to Raise USD20 Million in Subscription Rights Offering 29
XOMA Files Registration Statement for Public Offering of Securities 30
Xoma Raises USD25 Million in Registered Direct Offering of Shares 31
Xoma Raises USD40 Million in Private Placement of Shares and Warrants 32
Xoma Completes Public Offering Of Shares For US$57.4 Million 34
Xoma Completes Public Offering Of Shares For US$31.6 Million 36
Xoma Completes Public Offering Of Shares For US$40 Million 37
XOMA Completes Public Offering Of Common Stock For US$39 Million 39
Agenus Acquires Antibody Manufacturing Facilities from XOMA 41
Nanotherapeutics Ammends agreement with XOMA 43
CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 44
XOMA Corp, Key Competitors 45
XOMA Corp, Key Employees 46
XOMA Corp, Subsidiaries 47

List of Figures
XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[XOMA Corp (XOMA):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10127)販売に関する免責事項を必ずご確認ください。
★調査レポート[XOMA Corp (XOMA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆